Predict your next investment

HEALTHCARE | Biotechnology
fulcrumtx.com

See what CB Insights has to offer

Founded Year

2016

Stage

IPO | IPO

Total Raised

$140M

Date of IPO

7/18/2019

Market Cap

0.29B

Stock Price

9.08

About Fulcrum Therapeutics

Fulcrum Therapeutics (Nasdaq: FULC) is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum's therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes.

Fulcrum Therapeutics Headquarter Location

26 Landsdowne Street

Cambridge, Massachusetts, 02139,

United States

617-651-8851

Latest Fulcrum Therapeutics News

LoA Update: Fulcrum’s losmapimod progression chances to next development stage in facioscapulohumeral muscular dystrophy drops by 19 points after full Phase IIb data announced

Jul 1, 2021

By Reynald Castaneda 01 Jul 2021 (Last Updated July 1st, 2021 15:04) Fulcrum Therapeutics’ losmapimod for facioscapulohumeral muscular dystrophy (FSHD) had its Phase Transition Success Rate (PTSR) dive by 19 points to 9% after full Phase IIb trial data was revealed. Losmapimod is a p38alpha and beta mitogen activated protein kinase inhibitor. Share Article Fulcrum Therapeutics’ losmapimod for facioscapulohumeral muscular dystrophy (FSHD) had its Phase Transition Success Rate (PTSR) dive by 19 points to 9% after full Phase IIb trial data was revealed. Complete results from the 80-patient Phase IIb ReDUX4 trial (NCT04003974) were announced on 24 June, with its PTSR updated on 25 June. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next. In August 2020, Fulcrum announced interim ReDUX4 data covering 29 patients. It showed losmapimod does not offer improvement over placebo in the primary endpoint of DUX4-gene driven gene expression reduction from baseline at 16 weeks. On 24 June, the company announced full ReDUX4 data showing losmapimod still did not meet ReDUX4’s primary endpoint. This is despite the asset offering improvements over placebo with regards to structural and functional FSHD disease progression and patient-reported outcomes at 48 weeks. Fulcrum has said it will meet with regulatory authorities in 2H21 to discuss the regulatory path for losmapimod in FSHD. FSHD features muscle degeneration and fat infiltration, which initially affects movement in face and then eventually affects the arms, trunk, and legs. There are no approved FSHD therapies. Losmapimod is a p38alpha and beta mitogen activated protein kinase inhibitor. Its Likelihood of Approval (LoA) also reduced by 1 point to 2%. LoA is calculated by GlobalData’s analysis, uses a combination of machine learning and a proprietary algorithm. Fulcrum has a market cap of $293.8m. Reynald Castaneda is an Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this,  visit GlobalData . Related Companies

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Fulcrum Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Fulcrum Therapeutics is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

G

Google In Healthcare

61 items

The healthcare companies and initiatives that Google has invested in or is a part of

B

Biopharmaceuticals

5,726 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Fulcrum Therapeutics Patents

Fulcrum Therapeutics has filed 5 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Muscular dystrophy
  • Autosomal recessive disorders
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/24/2020

4/13/2021

Transcription factors, Epigenetics, Prodrugs, Proteins, Gene expression

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/24/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

4/13/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Transcription factors, Epigenetics, Prodrugs, Proteins, Gene expression

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Fulcrum Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Fulcrum Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.